Cephem compound having catechol group

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Shionogi & Co., Ltd. patent solves the following problem:

To date, a type of beta-lactam drugs and beta-lactam drugs were clinically very important antimicrobial drugs. However, there are increasing number of bacteria species have resistancy against beta-lactam drugs by producing beta-lactamase, which degrade beta-lactam drugs. According to Ambler molecular classification, beta-lactamase most classified into four classes. Specifically, the Class A (TEM, SHV, CTX-M type and the like), Class B (IMP range, vim, L-1 and the like), Class C (AMPC type) and Class D (OXA type and the like). Among them, class A, C and D forms that generally are classified into Serine-beta-lactamase, and on the other hand, Class B species are classified into metallo-beta-lactamase. It is known that both have every different mechanisms to one another in terms of the hydrolysis of the beta-lactam drugs.

Our analysis of this patent is as follows:

Shionogi & Co., Ltd.’s patent US 9145425 B2 deals with Cephem compound having catechol group.
This creation has Cephem compounds of formula: or an Ester, a protected compound at the amino on the ring in the 7-side chain, a pharmaceutically acceptable salt, or a solvate thereof, a pharmaceutical composition, and a method for the treatment of bacterial infectious diseases with the compound, Esther, the protected compound, salt, or solvate thereof, wherein the symbols in the formula described in the specification. The compounds exhibit potent antimicrobial spectrum against a variety of bacteria, including gram negative bacteria and / or programs positive bacteria, preferably the beta-lactamase producing programs negative bacteria, more preferably, multi-drug resistant microbials, in particular, Class B type metallo-beta- lactamase program negative bacteria, and still the best extended-spectrum beta-lactamase (ESBL) bacteria. The compounds most preferably not show cross-resistance against known Cephem carbapenem drugs or drugs.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Glioblastoma multiforme-reactive antibodies and methods of use thereof

Protect your invention by filing a Provisional or Utility Patent Application using our software today! It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The The Regents Of The University Of California patent solves the following problem:

Glioblastoma multiforme (GBM) is the most common and aggressive type of primary brain tumor, accounting for 52% of all cases of primary tumor brain and 20% of all intracranial tumors. The median survival time for a newly diagnosed patient approximately one year (Krex et al, Brain, 130 .: 2596-606, 2007). Current methods of treatment include chemotherapy, radiotherapy, and / or operations, that all palliative measures are not curative (Nicholas, Expert Rev Anticancer Father, 7: S23-7, 2007; Benitez et al, Curr Med Chem, 15: 729-42, 2008; Chang et al, Clin adv Hematol Oncol, 5: 894-902, 2007; and Reardon et al, Curr Treat Options Oncol, 9: 1-22, 2008). One problem with current methods of treatment is that even with all the gross surgical resection of the tumor with the best available treatment, return the tumor is nearly impossible to control, and therefore the long-term survival rate for GBM patients is extremely low.

Our analysis of this patent is as follows:

The Regents Of The University Of California’s patent US 9145462 B2 deals with Glioblastoma multiforme-reactive antibodies and methods of use thereof.
The present disclosure generally relates to the antibody that binds specifically with glioblastoma multiforme (GBM) cells. In particular, the present disclosure provides compositions comprising human chain or full-length antibodies that bind to tumor cells. Moreover the present disclosure provides methods of using the anti-GBM antibody.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Antibodies

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Affitech Research As patent solves the following problem:

With more than 800 members, G-protein-coupled receptor (GPCRs) represent the largest family of cell surface molecules involved in signal transmission, accounting for 2% of the total gene encoded human genome. The members of the GPCR share a common membrane Topology: an extracellular N-terminus, an intracellular C-terminus and seven transmembrane (TM) helices connected by three intracellular loops and three extracellular loops. On the basis of their shared topological structure, GPCRs are also referred to as seven transmembrane (7tm) receptor. These receptors control key physiological functions, including neurotransmission, hormone and enzyme release from endocrine and exocrine glands, immune responses, cardiac- and smooth-muscle and blood pressure regulation. Their dysfunction contributes to some of the most widespread human diseases. Emerging experimental and clinical data showed that GPCRs have an important role in cancer growth and metastasis. Therefore, the possibility exists that some GPCRs could be target for anti-cancer drugs.

Our analysis of this patent is as follows:

Affitech Research As’s patent US 9145461 B2 deals with Antibodies.
The present invention provides antibodies that bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and that is capable of inhibiting the binding of macrophage-derived chemokine (MDC) and / or thymus and activation regulated chemokine (TARC) CCR4. Also provides inter alia immunoconjugates and compositions comprising these antibodies and methods and uses involving the same antibody, particularly in the medical and diagnostic fields.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Lithographic apparatus and device manufacturing method

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Asml Netherlands B.V. patent solves the following problem:

A lithographic apparatus is a machine that applies a desired pattern onto a substrate, usually onto a target portion of the substrate. A lithographic apparatus can be used, for example, in the manufacture of integrated circuits (ICs). In time, a pattern maker, alternatively referred to as a mask or a reticle, can be used to generate a circuit pattern formed on an individual layer of the IC. This pattern can be transferred to a target segment (comprised of, one, or several dies) on a substrate (eg a silicon wafer). Transfer the pattern is usually by imaging onto a layer of radiation-sensitive material (resist) provided on the substrate. In general, a substrate consisting of a network of adjacent target portions that order followed. Known lithographic apparatus include so-called steppers, each target portion irradiated by exposing an entire pattern onto the target at a time, and so-called scanners, each target portion irradiated with scanning the pattern through a radiation beam in one direction (the scanning direction) while synchronously scanning the substrate parallel or anti-parallel to this direction. It is also possible to transfer the pattern from the following devices to the substrate by imprinting the pattern to the substrate

Our analysis of this patent is as follows:

Asml Netherlands B.V.’s patent US 9146478 B2 deals with Lithographic apparatus and device manufacturing method.
An immersion lithographic apparatus with adaptations to prevent or reduce Bubble formation of one or more gaps in the substrate table with foam to prevent escape from the gap in the beam path and / or getting bubbles that form gap.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Benzimidazole compounds and their use as chromatographic ligands

File for Quick & Easy Patent Protection with PowerPatent.

The Millipore (U.K.) Limited patent solves the following problem:

Immunoglobulin or antibody constitute a very important class of proteins found in various fluids of mammals, birds and fish functioning as protective agents in animals against these things, bacteria and virus to provoke the beast body. Immunoglobulin is usually in the blood of animals, milk, and saliva as well as in other body fluids and secretions.

Our analysis of this patent is as follows:

Millipore (U.K.) Limited’s patent US 9144757 B2 deals with Benzimidazole compounds and their use as chromatographic ligands.
The present invention provides a new method for the isolation and / or purification of immunoglobulin from a solution containing one or more immunoglobulin using a solid-phase matrix represented by formula: M-SP-L, where M is referred to a verse womb, SP denotes a spacer and L denotes a substituted benzimidazole ligand.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Method of weak partitioning chromatography

File for Quick & Easy Patent Protection with PowerPatent.

The Wyeth Llc patent solves the following problem:

Within the biotechnology industry, the purification of proteins on a commercial scale is a significant challenge to the development of artificial proteins for therapeutic and diagnostic purposes. Problems related to yield, purity, and throughput plague the manufacturing sector. With the advent of technology in artificial protein, a protein of interest can be a guide to culture eukaryotic or prokaryotic host cell lines engineered to express a gene encoding the protein. What results from the processes of the host cell culturing, however, is a mixture of the desired protein with dirty either obtained from the protein itself, such as protein variants, or from the host cell, such as host cell proteins. The use of artificial desired protein for pharmaceutical applications is contingent on being able to reliably recover sufficient protein levels of these impurities.

Our analysis of this patent is as follows:

Wyeth Llc’s patent US 9144755 B2 deals with Method of weak partitioning chromatography.
This invention relates to methods of using the weak division chromatography for purification of a product from a load fluid containing one or more impurities. Furthermore, the invention relates to methods of weak division chromatography described operating conditions that cause a medium to bind at least 1 mg of product per ml of medium, or on the other hand, is described in a separate, partition coefficient of at least 0.1.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Protein-polymer-drug conjugates

File for Quick & Easy Patent Protection with PowerPatent.

The Mersana Therapeutics, Inc. patent solves the following problem:

Traditionally, treatment primarily composed of small molecules that provided orally (as solid pills and liquids) or as injectables. Over the past three decades, the formulation (ie, composition control of routes and / or rate of drug delivery and allow the delivery of therapeutic agents where they are needed) become more common and complex. Nevertheless, many questions and challenges regarding the development of new treatments as well as mechanisms to administer them remain to be addressed. For example, many drugs present limited or otherwise reduced potencies and therapeutic effects because they are not generally under partial destruction before they reach a desired target body, or accumulate in tissues other than the target, or both.

Our analysis of this patent is as follows:

Mersana Therapeutics, Inc.’s patent US 9144615 B2 deals with Protein-polymer-drug conjugates.
A drug conjugate given here. conjugate composed of a protein based recognition molecules (PBRM) and a polymeric carrier substituted with one or more -LD-D, protein-based recognition molecules connected to the polymeric carrier LP . Each event D is independently a therapeutic agent with a molecular weight of 5 kDa. LD and LP linkers connecting the therapeutic agent and PBRM polymeric carrier each. said polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug conjugate PBRM described here, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with conjugates or their composition.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Scatterometry metrology methods and methods of modeling formation of a vertical region of a multilayer semiconductor substrate to comprise a scatterometry target

File for Quick & Easy Patent Protection with PowerPatent.

The Micron Technology, Inc. patent solves the following problem:

Lithography is used in various applications for the production of the structural design, for example in the manufacture of integrated circuits, flat panel displays, micro-electro-mechanical systems, micro-optical systems, etc. during the performance, a substrate is usually subjected to an array of lithography- etching steps to create the various parts that result in a desired pattern in the uppermost part of the substrate. The resulting pattern can be analyzed in a non-destructive way to use metrology techniques to determine, for example, placement and / or measure portions or spaces between the parts of the pattern, or to determine the thickness, or other qualities of the deposited material.

Our analysis of this patent is as follows:

Micron Technology, Inc.’s patent US 9146193 B2 deals with Scatterometry metrology methods and methods of modeling formation of a vertical region of a multilayer semiconductor substrate to comprise a scatterometry target.
A scatterometry target formed relative to a elevationally the outermost surface of a substrate includes portions of an Optical properties of the space race between the parts. substrate The spaced-apart parallel elongated barrier lines with an optical properties different from the space between the barrier lines. Ali lines are elevationally in parts target. The target segment, and the barrier coating lines in a same vertical regions of the substrate. Polarized electromagnetic radiation with several wavelengths that threaten to target scatterometry. Pitch ali lines is less than the smallest wavelength of damaging radiation. Ali lines reduce color variation below a detectable level for any polarized electromagnetic radiation through the elevationally in ali lines. Electromagnetic radiation reflected from the target scatterometry from impinging detected, and it is a property associated with the portion of the target and / or the space between the portion of the target determined.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Regio- and enantioselective alkane hydroxylation with modified cytochrome P450

File for Quick & Easy Patent Protection with PowerPatent.

The The California Institute Of Technology patent solves the following problem:

Cytochrome P450s are a large class of enzymes that are primarily hydroxylate substrates using dioxygen, although other redox-type reactions, including some reductions, the report. Another, cytochrome P450 BM-3 is found in the bacteria Bacillus megaterium (EC 1.14.14.1). The other, known as CYP102, is a water-soluble, catalytically self-sufficient P450 consisting of a monooxygenase domain (64 KD) and a reductase domain (54 KD) in a polypeptide chains (Narhi and Fulco, Journal of Biological Chemistry, 261 (16): 7160-7169 (1986) and Journal of Biological Chemistry, 262 (14): 6683-6690 (1987); Miura and Fulco, Biochimica et Biophysica Acta, 388 (3): 305-317 (1975); Ruettinger et al., 1989). The minimum requirement for the activity of BM-3 other substrate, dioxygen and the cofactor nicotinamide adenine dinucleotide phosphate (NADPH). Nucleotide and amino acid sequences for the P450 BM-3 is found, and it was included in the discussion from the GenBank database under the throne Nos J04832 (SEQ ID NO: 1). And P14779 (SEQ ID NO: 2), respectively.

Our analysis of this patent is as follows:

The California Institute Of Technology’s patent US 9145549 B2 deals with Regio- and enantioselective alkane hydroxylation with modified cytochrome P450.
Cytochrome P450 BM-3 from Bacillus megaterium was engineered using a combination of directed evolution and site-directed mutagenesis to hydroxylate linear alkanes regio- and enantioselectively using atmospheric dioxygen as an oxidant. Mutant 9-10A-A328V hydroxylates octane primarily the 2-position to form S-2-octanol (40% ee). Another normal, 1-12G, hydroxylates alkanes greater than hexane primarily the 2-position, but forms R-2-alcohol (40-55% ee). These biocatalysts very active for alkane substrates and supporting thousands of turnovers products. These regio- and enantio-selectivities retained in whole-cell biotransformations of E. coli, which are engineered P450s may be expressed at high levels and the expensive cofactor provided endogenously.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Extracting multiple facial photos from a video clip

Protect your invention by filing a Provisional or Utility Patent Application using our software today! It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Evernote Corporation patent solves the following problem:

Now the solution for contact management includes a list of contacts in Personal Information Management (PIM) software, buddy lists, relatives, contacts, friends, circles, members and other individuals and contact groups concept now in desktop, mobile devices, as well as general purpose and professional network. These solutions emphasize the presence and sometimes the connection between categories of participants (such as former colleagues, to do business together, referred to in the third person, etc.) but often offer small tools and information to help understand the situation and the history of the relationship between contacts with others in their meetings and in one another's experiences. An increasing number of people meeting each other for the first time in a social environment lacking easy-to-use, fast, compelling and socially acceptable tools for the exchange of personal information between on their mobile devices and capture personal context and dynamics within the contact management applications. It should also be noted that the members of the social network were meeting each other in person rarely need replacing large amounts of personal information contact among them: once on a key piece of the information, an email address, known, others can often be obtained from the social network.

Our analysis of this patent is as follows:

Evernote Corporation’s patent US 9147131 B2 deals with Extracting multiple facial photos from a video clip.
Getting an optimal subset of faces included in gaining an initial set of face photographs, removing from the first set photos in any photo that is unacceptable quality, combined with a remaining group the standpoint that angle, away from the remaining set of photos in any picture that has a bad facial expressions provide a limited set of representative face, and, picking , from the limited set of face photographs, an optimal subset of face photographs. In taking the initial set of photos may include use of a video camera during different view angle and control the quality of recording. In taking the initial set of photos may include obtaining a series of still images. The pictures still be self-recorded at a man with a Smartphone front-facing camera.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.